IEHP UM Subcommittee Approved Authorization Guideline

<table>
<thead>
<tr>
<th>Guideline</th>
<th>Liver Biopsy in Conjunction with Bariatric Surgery</th>
<th>Guideline #</th>
<th>UM SUR 05</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section</td>
<td>Surgery</td>
<td>Original Effective Date</td>
<td>8/11/2010</td>
</tr>
<tr>
<td>Revision Date</td>
<td></td>
<td></td>
<td>11/14/2018</td>
</tr>
</tbody>
</table>

COVERAGE POLICY
IEHP does not cover routine liver biopsy in conjunction with bariatric surgery due to insufficient evidence that such practice alters the clinical management of non-alcoholic fatty liver disease (NAFLD) in obese individuals.

If a provider is concerned about a disease process in the liver the patient can be further assessed through laboratory analysis (e.g., liver function tests), imaging studies (e.g., ultrasound), and predictive scores/indices (e.g., NAFLD Fibrosis Score, aminotransferase-to-platelet ratio index [APRI], Enhanced Liver Function [ELF] score, etc.), (Angulo, Hui, Marchesini, et al, 2007). Should these non-invasive modalities support the diagnosis of NAFLD or co-morbid metabolic syndrome in a bariatric surgery candidate, it is important to rule-out competing etiologies for liver disease (e.g., viral infections, autoimmune processes, and alcohol use) prior to proceeding with an intraoperative liver biopsy (IOLB), (Chalasani, Younossi, Lavin, et al, 2012).

COVERAGE LIMITATIONS AND EXCLUSIONS
N/A

ADDITIONAL INFORMATION
Obesity is a topic of increasing public health concern in the United States, with over one-third of the population categorized as obese (e.g., body mass index or BMI > 30). Obesity is linked to a number of chronic health conditions, including diabetes mellitus and heart disease, and has been associated with an increased mortality rate. However, the prevalence of the NAFLD spectrum – which encompasses simple steatosis, Non-Alcoholic Steatohepatitis (NASH), advanced fibrosis, and cirrhosis – in obese individuals has yet to be fully characterized. For this reason, some practitioners consider IOLB in conjunction with bariatric surgery to be a reasonable option for identifying disease in bariatric surgery candidates. However, since weight loss remains the best known treatment for NAFLD and bariatric surgery (presumably) will promote weight loss in obese patients regardless of their liver disease status, IOLB in conjunction with bariatric surgery does not appear to affect the clinical management of NAFLD. Additionally, information and recommendations related to post-surgical follow-up (including interval liver biopsy to monitor disease progression/regression) remain absent from current literature.

There have been several articles based on case series and cohort studies that appear in obesity surgery-related journals recommending IOLB in conjunction with bariatric surgery to distinguish NASH from NAFLD involving simple steatosis, (Dolce, Russo, et al, 2009; Kleiner, Berk, et al, 2014). However, no randomized clinical trials have compared outcomes between patients receiving IOLB and those receiving usual care. Furthermore, recent review articles have

A recent review of the role of routine liver biopsy during bariatric surgery highlights the fact that while nearly a quarter of western world suffers from NAFLD, the role of screening is not well established (Mahawar, Parmar, et al, 2016). The authors reason that “if screening biopsies are not recommended for obese patients in general, it is hard to see how patients undergoing bariatric surgery would benefit from such biopsies.” Moreover, since “bariatric surgery actually alters the natural course of [NAFLD],” they conclude that the “existing scientific literature does not make a compelling case for routine liver biopsy with bariatric surgery.”

In another review it was noted that interoperative liver biopsy is still the gold standard for diagnosing the degree of NAFLD (Barbois, Arvieux, Leroy, et al 2017). Despite this, based on meta-analysis, only 25% of patients undergoing bariatric surgery have NASH which would require IOLB to confirm the diagnosis. Therefore, they conclude that the risk of routine IOLB to those who only have simple steatosis or no liver disease is unacceptable and they do not recommend routine IOLB. Alternatively, they propose that an algorithm of noninvasive tests needs to be developed and validated to determine who requires IOLB and those who do not.

---

**CLINICAL/REGULATORY RESOURCE**

**Centers for Medicare and Medicaid Services (CMS) / Medi-Cal**

CMS and Medi-Cal provide no specific policies addressing routine IOLB in conjunction with bariatric surgery.

**MCG Medical Guidelines**

MCG provides no specific guidelines addressing routine IOLB in conjunction with bariatric surgery.

**The American Association of Clinical Endocrinologists (AACE), The Obesity Society, and the American Society for Metabolic and Bariatric Surgery (ASMBS) Clinical Practice Guidelines (March 2013)**

The AACE, Obesity Society, and ASMBS have jointly issued a Grade D recommendation (i.e., based on expert opinion because of lack of conclusive evidence) for liver biopsy in the perioperative evaluation of a bariatric surgery patient, indicating that “consideration can be made for liver biopsy at the time of surgery to document steatohepatitis and/or cirrhosis that may otherwise be unknown due to normal appearance and/or liver function tests.”

**The American Association for the Study of Liver Diseases (AASLD), the American College of Gastroenterology (ACG), and the American Gastroenterological Association (AGA) Clinical Practice Guidelines (June 2012) and Practice Guidance (January 2018)**

The AASLD, ACG, and AGA have jointly developed practice guidelines in 2012 and updated them with a guidance document in 2018. They have issued a Strength 1/Evidence B recommendation (e.g., strong, but further research may change confidence in the estimate of clinical effect) against routine screening for NAFLD in obesity clinics; a Strength 1/Evidence B recommendation indicating that the presence of the metabolic syndrome and the NAFLD Fibrosis Score may be used for identifying those at high risk for steatohepatitis and advanced
cirrhosis; and a Strength 1/Evidence B recommendation for the consideration of liver biopsy in individuals with suspected NAFLD in whom competing etiologies for hepatic steatosis and the presence and/or severity of co-existing chronic liver disease cannot be excluded without liver biopsy.

**DEFINITION OF TERMS**

N/A

**REFERENCES**


**DISCLAIMER**

IEHP Clinical Authorization Guidelines (CAG) are developed to assist in administering plan benefits, they do not constitute a description of plan benefits. The Clinical Authorization Guidelines (CAG) express IEHP’s determination of whether certain services or supplies are medically necessary, experimental and investigational, or cosmetic. IEHP has reached these conclusions based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). IEHP makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in the Clinical Authorization Guidelines (CAG). IEHP expressly and solely reserves the right to revise the Clinical Authorization Guidelines (CAG), as clinical information changes.